Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Jun 21, 2023; 29(23): 3658-3667
Published online Jun 21, 2023. doi: 10.3748/wjg.v29.i23.3658
Table 1 Basic characteristics according to serum and glucocorticoid-induced protein kinase 3 expression status
Characteristics
SGK3 normal, n = 37
SGK3 overexpression, n = 55
P value
Age (yr, mean ± SD)58.73 ± 6.8161.21 ± 8.050.118
Sex (male), n (%)27 (73.0)36 (65.5)0.447
Tumor location, n (%)10.560
    Upper esophagus4 (10.8)7 (12.7)
    Middle esophagus14 (37.8)26 (47.)
    Lower esophagus19 (51.4)22 (40.0)
Tumor size (cm, mean ± SD)3.16 ± 1.943.30 ± 1.890.742
Tumor stage, n (%)0.720
    Tis25 (67.6)38 (69.1)
    T1a6 (16.2)11 (20.0)
    T1b6 (16.2)6 (10.9)
Differentiated types1, n (%)0.487
    HIN25 (67.6)39 (70.9)
    Well-differentiation7 (18.9)13 (23.6)
    Intermediate differentiation2 (5.4)2 (3.6)
    Poor differentiation3 (8.1)1 (1.8)
Smoking history, n (%)0.313
    Yes10 (27.0)10 (18.2)
    No27 (73.0)45 (81.8)
Lymphovascular infiltration, n (%)10.402
    Present1 (2.7)0 (0)
    Absent36 (97.3)55 (100)
Family history of cancer1, n (%)0.698
    Yes2 (5.4)5 (9.1)
    No35 (94.6)50 (90.9)
Table 2 Prognosis outcomes in the serum and glucocorticoid-induced protein kinase 3 normal and overexpression groups
Prognosis factors, n (%)
SGK3 normal, n = 37
SGK3 overexpression, n = 55
P value
Tumor recurrence1, n (%)0.306
    Present2 (5.4)8 (14.5)
    Absent35 (94.6)47 (85.5)
Metastasis1, n (%)0.402
    Present1 (2.7)0 (0)
    Absent36 (97.3)55 (100)
Death1, n (%)0.031
    Yes3 (8.1)15 (27.3)
    No34 (91.9)40 (72.7)
Table 3 Hazard ratio (95% confidence interval) for all-cause mortality between serum and glucocorticoid-induced protein kinase 3 normal and serum and glucocorticoid-induced protein kinase 3 overexpression
Model
HR (95%CI)
P value
Model 14.243 (1.219-14.773)0.023
Model 23.648 (1.030-12.917)0.045
Model 33.637 (1.028-12.866)0.045
Model 44.729 (1.042-21.458)0.044